Retatrutide just delivered Phase 3 results that redefine what’s possible in pharmaceutical weight loss—and raised new questions about tolerability. Eli […]
A landmark study on GLP-1 side effects just surfaced symptoms that clinical trials may be missing. A team at the
Eli Lilly’s retatrutide — the first triple-hormone-receptor agonist (GLP-1, GIP, and glucagon) — posted striking Phase 3 results from the TRIUMPH program,
Two recently published reviews have mapped the full landscape of BPC-157 research — and the picture they paint is simultaneously impressive